According to DART periodic reports, annual revenue was KRW 27.1 billion in 2022, KRW 30.9 billion in 2023 (up 13.8% year on year), KRW 40.4 billion in 2024 (up 30.9%), and KRW 51.7 billion in 2025 (up 27.9%).
Revenue has increased for three consecutive years from 2023 through 2025, and 2025 was the largest year of 2022 to 2025. Operating profit was KRW 3.68 billion in 2022, fell to KRW 3.34 billion in 2023 (down 9.3%), then rose to KRW 3.85 billion in 2024 (up 15.2%) and KRW 3.92 billion in 2025 (up 1.7%).
Operating profit has increased for two consecutive years from 2024 through 2025, and 2023 was the smallest year. Revenue grew, but the operating margin declined every year, from 13.6% in 2022 to 10.8% in 2023, 9.5% in 2024 and 7.6% in 2025, so top-line growth did not translate into better margins.
Net income attributable to controlling shareholders fell from KRW 4.31 billion in 2022 to KRW 2.83 billion in 2023 (down 34.5%) and KRW 1.32 billion in 2024 (down 53.4%). It then turned into a net loss of KRW 3.63 billion in 2025.
Net income including non-controlling interests was a net loss of KRW 3.49 billion in 2025.
In the first half of 2025, the consolidation of Intro Biopharma lifted sales growth, but higher R&D spending and selling and administrative costs from headcount additions reduced profitability, according to a November 2025 brokerage analysis.
Quarterly results show that operating profit was KRW 1.14 billion in the third quarter of 2025, then fell to KRW 610 million in the fourth quarter (down 46.6% from the prior quarter), when net income attributable to controlling shareholders swung to a net loss of KRW 2.68 billion.
In the first quarter of 2026, revenue was KRW 11.9 billion and the company posted an operating loss of KRW 172 million. A press report at the time cited higher R&D and new-business costs as the reason.
In the second quarter of 2026, revenue was KRW 12.9 billion and operating profit returned to KRW 1.03 billion, with net income attributable to controlling shareholders of KRW 851 million.
In the third quarter of 2026, revenue was KRW 12.5 billion (down 6.5% year on year), operating profit was KRW 255 million (down 77.7% year on year), and net loss attributable to controlling shareholders was KRW 190 million.
Across the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, the combined net loss attributable to controlling shareholders was KRW 1.93 billion.